ES2128090T3 - Procedimiento para la extraccion del factor willebrand de alta pureza. - Google Patents
Procedimiento para la extraccion del factor willebrand de alta pureza.Info
- Publication number
- ES2128090T3 ES2128090T3 ES95935890T ES95935890T ES2128090T3 ES 2128090 T3 ES2128090 T3 ES 2128090T3 ES 95935890 T ES95935890 T ES 95935890T ES 95935890 T ES95935890 T ES 95935890T ES 2128090 T3 ES2128090 T3 ES 2128090T3
- Authority
- ES
- Spain
- Prior art keywords
- willebrand factor
- rvwf
- free
- extraction
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA INVENCION TRATA DE UN PROCEDIMIENTO PARA LA RECUPERACION DEL FACTOR DE WILLEBRAND CON ELEVADA PUREZA, EN EL CUAL EL RECOMBINANTE DEL FACTOR DE WILLEBRAND (RVWF) SE PURIFICA CROMATOGRAFICAMENTE POR CROMATOGRAFIA DE INTERCAMBIO ANIONICO CON UN INTERCAMBIADOR ANIONICO DEL TIPO DE AMINA CUATERNARIA EN UNA SOLUCION AMORTIGUADORA, QUE COMPRENDE SUSTANCIAS AMORTIGUADORAS Y OPCIONALMENTE SAL. LAS SOLUCIONES AMORTIGUADORAS ESTAN PREFERENTEMENTE SIN ESTABILIZANTES, AMINOACIDOS Y OTROS ADITIVOS. SEGUN ESTE PROCEDIMIENTO SE OBTIENE RECOMBINANTE DE VWF CON ELEVADA PUREZA, SIN PROTEINAS PLASMATICAS DE LA SANGRE, EN PARTICULAR SIN EL FACTOR VIII, Y FISIOLOGICAMENTE ACTIVO. LA INVENCION TAMBIEN TRATA DE UNA PREPARACION FARMACEUTICA, QUE CONTIENE RVWF, Y QUE SE COMPONE DE MULTIMEROS CON UNA INTEGRIDAD ESTRUCTURAL ELEVADA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4435485A DE4435485C1 (de) | 1994-10-04 | 1994-10-04 | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2128090T3 true ES2128090T3 (es) | 1999-05-01 |
Family
ID=6529944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95935890T Expired - Lifetime ES2128090T3 (es) | 1994-10-04 | 1995-10-02 | Procedimiento para la extraccion del factor willebrand de alta pureza. |
Country Status (11)
Country | Link |
---|---|
US (4) | US5854403A (es) |
EP (1) | EP0784632B1 (es) |
JP (1) | JP3701028B2 (es) |
AT (1) | ATE175424T1 (es) |
AU (1) | AU698334B2 (es) |
CA (1) | CA2201714C (es) |
DE (2) | DE4435485C1 (es) |
DK (1) | DK0784632T3 (es) |
ES (1) | ES2128090T3 (es) |
GR (1) | GR3029837T3 (es) |
WO (1) | WO1996010584A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880327A (en) * | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
DE19616540A1 (de) * | 1995-11-10 | 1997-05-15 | Immuno Ag | Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung |
US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
US6068838A (en) * | 1996-04-29 | 2000-05-30 | Baxter Aktiengesellschaft | Purified multimerase |
AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
AT406867B (de) | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
JP4216478B2 (ja) | 1998-09-21 | 2009-01-28 | パーダム、ハワード・イー | 感温性の材料を処理する方法および装置 |
WO2001022810A2 (en) * | 1999-09-28 | 2001-04-05 | Us Transgenics, Inc. | Transgenic animals expressing von willebrand factor (vwf) and vwf-related polypeptides |
US20040185042A1 (en) | 2003-03-20 | 2004-09-23 | Friedrich Scheiflinger | Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies |
CA2531581A1 (en) * | 2003-07-07 | 2005-01-27 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
US7771660B2 (en) | 2004-05-04 | 2010-08-10 | University Of North Carolina At Chapel Hill | Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles |
FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
CA2579374A1 (en) | 2004-09-07 | 2006-03-30 | Archemix Corp. | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
JP2008512097A (ja) | 2004-09-07 | 2008-04-24 | アーケミックス コーポレイション | アプタマー医薬品化学 |
WO2006071801A2 (en) | 2004-12-27 | 2006-07-06 | Baxter International Inc | Polymer-von willebrand factor-conjugates |
AU2007245190B2 (en) | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
CA2690218C (en) | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
EP2073015A1 (en) | 2007-12-21 | 2009-06-24 | CSL Behring GmbH | Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function |
US20100273206A1 (en) * | 2007-12-21 | 2010-10-28 | Manfred Rauh | Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function |
BRPI0821474B8 (pt) | 2007-12-28 | 2021-05-25 | Baxalta GmbH | formulação farmacêutica líquida estável |
AU2014202595A1 (en) * | 2007-12-28 | 2014-06-05 | Baxalta GmbH | Recombinant VWF Formulations |
US11197916B2 (en) * | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
KR101507718B1 (ko) | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체 |
TWI508735B (zh) * | 2008-10-21 | 2015-11-21 | 巴克斯特國際公司 | 凍乾的重組vwf調配物 |
KR20120061898A (ko) | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
EP2499165B1 (en) | 2009-11-13 | 2016-09-14 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
US9488625B2 (en) | 2010-12-15 | 2016-11-08 | Baxalta GmbH | Purification of factor VIII using a conductivity gradient |
HUE039317T2 (hu) * | 2011-06-10 | 2018-12-28 | Baxalta GmbH | Koagulációs betegség kezelése rekombináns VWF adagolásával |
EP2748180B1 (en) * | 2011-10-14 | 2018-08-15 | Baxalta GmbH | Protein purification by anion exchange chromatography |
KR20140083036A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도 |
AU2012318303B2 (en) | 2011-10-18 | 2015-09-03 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
US20140206844A1 (en) | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
WO2015066769A1 (en) | 2013-11-08 | 2015-05-14 | Csl Ltd. | New method to concentrate von willebrand factor or complexes thereof |
CA2953593C (en) | 2014-07-02 | 2023-09-26 | Csl Limited | Modified von willebrand factor |
US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
CN108779165B (zh) | 2016-01-07 | 2022-12-02 | 康诺贝林伦瑙有限公司 | 突变的冯·维勒布兰德因子 |
JP6851381B6 (ja) | 2016-01-07 | 2021-04-21 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 変異切断型フォンウィルブランド因子 |
DK3648788T3 (da) | 2017-07-07 | 2024-08-19 | Takeda Pharmaceuticals Co | Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf |
CN110997015A (zh) | 2017-08-23 | 2020-04-10 | 德国杰特贝林生物制品有限公司 | 用于von Willebrand因子的病毒过滤的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
NL8500961A (nl) * | 1985-04-01 | 1986-11-03 | Stichting Vrienden Van De Stic | Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten. |
FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
DE3904354A1 (de) * | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
FR2665449B1 (fr) * | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
EP0431129B1 (en) * | 1989-06-15 | 1996-05-29 | Rorer International (Overseas) Inc. | Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions |
FR2651437A1 (fr) * | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
US5312747A (en) * | 1990-12-17 | 1994-05-17 | Li Yu Teh | Isolation, purification and utilization of sialidase-L in the synthesis of 2,7-anhydro-N-acetylneuraminic acid and for the selective cleavage of sialylα2-3 D-galactose linkage |
FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
IT1256622B (it) * | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
JP3133338B2 (ja) * | 1992-12-16 | 2001-02-05 | イムノ・アクチエンゲゼルシャフト | ウイルス的に安全な生物学的組成物の調製方法 |
DE4434538C2 (de) * | 1993-10-06 | 2000-08-10 | Immuno Ag | Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens |
-
1994
- 1994-10-04 DE DE4435485A patent/DE4435485C1/de not_active Expired - Fee Related
-
1995
- 1995-10-02 JP JP51140796A patent/JP3701028B2/ja not_active Expired - Fee Related
- 1995-10-02 AU AU38031/95A patent/AU698334B2/en not_active Ceased
- 1995-10-02 CA CA002201714A patent/CA2201714C/en not_active Expired - Fee Related
- 1995-10-02 DE DE59504750T patent/DE59504750D1/de not_active Expired - Lifetime
- 1995-10-02 AT AT95935890T patent/ATE175424T1/de active
- 1995-10-02 ES ES95935890T patent/ES2128090T3/es not_active Expired - Lifetime
- 1995-10-02 DK DK95935890T patent/DK0784632T3/da active
- 1995-10-02 WO PCT/EP1995/003892 patent/WO1996010584A1/de active IP Right Grant
- 1995-10-02 EP EP95935890A patent/EP0784632B1/de not_active Expired - Lifetime
-
1996
- 1996-05-24 US US08/653,298 patent/US5854403A/en not_active Expired - Lifetime
-
1997
- 1997-07-22 US US08/898,131 patent/US5877152A/en not_active Expired - Lifetime
- 1997-07-22 US US08/898,130 patent/US6103693A/en not_active Expired - Lifetime
- 1997-07-22 US US08/898,129 patent/US5880265A/en not_active Expired - Lifetime
-
1999
- 1999-03-31 GR GR990400931T patent/GR3029837T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2201714C (en) | 2002-07-02 |
DK0784632T3 (da) | 1999-08-30 |
WO1996010584A1 (de) | 1996-04-11 |
EP0784632B1 (de) | 1999-01-07 |
JP3701028B2 (ja) | 2005-09-28 |
CA2201714A1 (en) | 1996-04-11 |
ATE175424T1 (de) | 1999-01-15 |
US5854403A (en) | 1998-12-29 |
GR3029837T3 (en) | 1999-06-30 |
AU698334B2 (en) | 1998-10-29 |
DE59504750D1 (de) | 1999-02-18 |
US5877152A (en) | 1999-03-02 |
US6103693A (en) | 2000-08-15 |
US5880265A (en) | 1999-03-09 |
DE4435485C1 (de) | 1996-03-21 |
EP0784632A1 (de) | 1997-07-23 |
JPH11509721A (ja) | 1999-08-31 |
AU3803195A (en) | 1996-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2128090T3 (es) | Procedimiento para la extraccion del factor willebrand de alta pureza. | |
US4877608A (en) | Pharmaceutical plasma protein formulations in low ionic strength media | |
Calvete et al. | A procedure for the large-scale isolation of major bovine seminal plasma proteins | |
Selsted et al. | Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. | |
US5605884A (en) | Factor VIII formulations in high ionic strength media | |
US5208041A (en) | Essentially pure human parathyroid hormone | |
EP0314095B1 (en) | Plasma and recombinant protein formulation in high ionic strength media | |
RU93046317A (ru) | Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции | |
CA2099138A1 (en) | Chondroitinase, Process for Preparing the Same, and Pharmaceutical Composition Comprising the Same | |
ES8702432A1 (es) | Procedimiento para la purificacion de una proteina | |
DE69329367D1 (de) | Wachstumshormon-enthaltendeproteinformulierung | |
KR920701255A (ko) | 에리쓰로포이에틴 동형체(eryihropoietin isoform) | |
JP2002097199A (ja) | 安定化された第viii因子調製物 | |
Linde et al. | Evidence for several γ-carboxyglutamic acid-containing proteins in dentin | |
BR9907995A (pt) | Métodos imunológicos para modular miostatina em sujeitos vertebrados | |
RU2002117383A (ru) | Способ очистки фармакологически активных белков с помощью катионообменной хроматографии | |
Rathnam et al. | Subunits of luteinizing hormone from human pituitary glands | |
CA2282841C (en) | A method of purifying factor viii/vwf-complex by means of cation exchange chromatography | |
EP0469985A1 (en) | Process for manufacturing von Willebrand factor having a very high purity | |
CA2683317C (en) | Stabilization of liquid solutions of recombinant protein for frozen storage | |
AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
Kotite et al. | Subunit structure of rabbit testosterone estradiol-binding globulin. | |
Schmid et al. | Disulfide bonds of α1-acid glycoprotein | |
KR860008270A (ko) | α-인터페론의 제조 및 정제 방법 | |
Ebert et al. | Isolation and comparative peptide mapping of fibrinogen subunits by reversed-phase high-performance liquid chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 784632 Country of ref document: ES |